Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Next-generation Vitamin D Expected to Be Effective for Colon Cancer: Chugai Seminar
March 12, 2001
- IFPMA Creates Task Force on Access to Anti-AIDS Drugs
March 12, 2001
- Actelion to Launch First Endothelin Receptor Antagonists: JPLA Meeting
March 12, 2001
- Mitsubishi Chemical, Fujitsu Tie Up for Bioinformatics
March 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 12, 2001
- Tanabe Licenses PDE5 Inhibitor to Vivus
March 12, 2001
- Panic Disorder Is Curable by Drug Therapy: GSK Seminar
March 12, 2001
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -1-
March 12, 2001
- BUSINESS NEWS IN BRIEF -1-
March 12, 2001
- Fujisawa Ties Up with Fuji RC for Respiratory Care Devices
March 5, 2001
- Dissolution Test Methods Proposed for 13 Active Ingredients
March 5, 2001
- MIC Receives Applications for Clinical Trials via Toll-free Dial
March 5, 2001
- Nomura Securities Starts Nomura Bio Network
March 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 5, 2001
- Novartis: Group Sales Up 10% to CHF 35.8 Bil.
March 5, 2001
- 60% of Manufacturer-hired MRs Are Interested in Contract MRs
March 5, 2001
- Korosho to Present Drug Pricing Reform Policy by Summer
March 5, 2001
- Raloxifene Reduces Risk of Breast Cancer
March 5, 2001
- BULLETIN
March 5, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…